Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151603 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3686565 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3152635 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13450787 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL1924296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL14547320 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7628296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3156153 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3147308 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL21622002 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-15 | — | — | US | claimed |
| US-10744094-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-08-18 | — | — | US | claimed |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-07-25 | — | — | US | claimed |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-04-11 | — | — | US | claimed |
| EP-2575798-B1 | GASTRORETENTIVE DOSAGE FORMS OF GABA ANALOGS | RUBICON RES PRIVATE LTD (IN) | 2017-08-09 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC. (US) | 2014-07-24 | — | — | US | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20040176456-A1 | Method of treatment for sexual dysfunction | TAYLOR CHARLES PRICE (US) | 2004-09-09 | — | — | US | claimed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | claimed |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | PFIZER INC | 2004-07-22 | — | — | US | claimed |
| US-20040116525-A1 | Cyclic nitromethyl acetic acid derivatives | DERRICK ANDREW MICHAEL (GB) | 2004-06-17 | — | — | US | claimed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | claimed |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BLAKEMORE DAVID CLIVE (GB) | 2004-05-13 | — | — | US | claimed |
| US-6596900-B2 | Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents | PFIZER INC | 2003-07-22 | — | — | US | claimed |
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | PFIZER INC. | 2003-04-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176456-A1 | Method of treatment for sexual dysfunction | SHBG, CHRND, ADRB2 | CYP1A2 1173/4885USP2 2021/4885ALDH1A1 1007/4885 |
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | AADAT, SLC1A2, BCAT1 | CYP1A2 966/4885USP2 4035/4885ALDH1A1 1302/4885 |
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | CYP1A2 772/4885USP2 1206/4885ALDH1A1 2863/4885 |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | CYP1A2 772/4885USP2 1206/4885ALDH1A1 2863/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | CYP1A2 1219/4885USP2 2446/4885ALDH1A1 1358/4885 |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | CHRND, CHRNG, CHRNE | CYP1A2 1702/4885USP2 2312/4885ALDH1A1 1176/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | CYP1A2 772/4885USP2 1206/4885ALDH1A1 2863/4885 |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BCAT1, BCAT2, AADAT | CYP1A2 2278/4885USP2 3447/4885ALDH1A1 3565/4885 |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | CYP1A2 772/4885USP2 1206/4885ALDH1A1 2863/4885 |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | CYP1A2 538/4885USP2 711/4885ALDH1A1 1356/4885 |
| US-10744094-B2 | Extended release pharmaceutical formulation | CRH, HTR5A, HTR6 | CYP1A2 538/4885USP2 711/4885ALDH1A1 1356/4885 |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | CYP1A2 1017/4885USP2 4154/4885ALDH1A1 1636/4885 |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | CYP1A2 538/4885USP2 711/4885ALDH1A1 1356/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | CYP1A2 1219/4885USP2 2446/4885ALDH1A1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.